Inhibitory effects of some derivatives of glycyrrhizic acid against Epstein-Barr virus infection: Structure-activity relationships

Antiviral Research

Volumn 79, Issue 1, 2008, Pages 6-11

  Lin, Jung Chung ^a   Cherng, Jaw Ming ^b   Hung, Man Shan ^a   Baltina, Lidia A ^c,d   Baltina, Lia ^c,d   Kondratenko, Rimma ^d  

^a TZU CHI UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY BEIGANG HOSPITAL   (Taiwan)

^c INSTITUTE OF ORGANIC CHEMISTRY   (Russian Federation)

^d BASHKIR STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Antiviral activity; Epstein Barr virus; Glycyrrhizic acid derivatives

Indexed keywords

18 BETA GLYCYRRHETINIC ACID; AMINO ACID; AMMONIA; CARBOXYL GROUP; GLYCYRRHIZIC ACID DERIVATIVE; HYDROXYL GROUP; POTASSIUM SALT; VIRUS ANTIGEN; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RAJI CELL; STRUCTURE ACTIVITY RELATION; VIRUS INFECTION; VIRUS REPLICATION;

ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPSTEIN-BARR VIRUS INFECTIONS; GENE DOSAGE; GENOME, VIRAL; GLYCYRRHIZIC ACID; HERPESVIRUS 4, HUMAN; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

HUMAN HERPESVIRUS 4;

EID: 43049129921     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.01.160     Document Type: Article

References (48)

1. Abe N., Akbar S.M.F., Hasebe A., Horiike N., and Onji M. Glycyrrhizin enhances interleukin-10 production by liver dendritic cells in mice with hepatitis. J. Gastroenterol. 38 (2003) 962-967
2. Armanini D., Fiore C., Mattarello M.J., Bielenberg J., and Palermo M. History of the endocrine effects of licorice. Exp. Clin. Endocrinol. Diabetes 110 (2002) 257-261
3. Baltina L.A. Chemical modification of glycyrrhizic acid as a route to new bioactive compounds for medicine. Curr. Med. Chem. 10 (2003) 155-171
4. Baltina Jr. L.A., Kondratenko R.M., Baltina L.A., Plyasunova O.A., Galin F.Z., and Tolstikov G.A. Synthesis of glycyrrhizic acid conjugates containing l-lysine. Chem. Nat. Comp. 42 (2006) 543-548
5. Bean P. Containing the spread of HIV infection among high-risk groups. Am. Clin. Lab. 21 (2002) 19-21
6. Briolant S., Garin D.N., Scaramozzino A., Jouan N., and Crance J.M. In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antiviral Res. 61 (2004) 111-117
7. 1-induced cytotoxicity in hepatoma cells. Toxicology 188 (2003) 211-217
8. Cherng J.-M., Lin H.J., Hsu Y.-H., Hung M.-S., and Lin J.-C. A quantitive bioassay for HIV-1 gene expression based on UV-activation: effect of glycyrrhizic acid. Antiviral Res. 62 (2004) 27-36
9. Cherng J.-M., Lin H.-J., Hung M.-S., Lin Y.-R., Chan M.-H., and Lin J.-C. Inhibition of nuclear factor κB is associated with neuroprotective effects of glycyrrhizic acid on glutamate-induced excitotoxicity in primary neurons. Eur. J. Pharmacol. 547 (2006) 10-21
10. Cinatl J., Morgenstem B., Bauer G., Chandra P., Rabenau H., and Doerr H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361 (2003) 2045-2046
11. Cinatl J., Michaelis M., Hoever G., Preiser W., and Doerr H.W. Development of antiviral therapy for severe acute respiratory syndrome. Antiviral Res. 66 (2005) 81-97
12. Coon J.T., and Ernst E. Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review. J. Hepatol. 40 (2004) 491-500
13. Crance J.M., Scaramozzino N., Jouan A., and Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res. 58 (2003) 73-79
14. Dirnagl U., Iadecola C., and Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22 (1999) 391-397
15. Fiore C., Salvi M., Palermo M., Sinigaglia G., Armanini D., and Toninello A. On the mechanism of mitochondrial permeability transition induction by glycyrrhetinic acid. Biochim. Biophys. Acta 1658 (2004) 195-201
16. Fujisawa Y., Sakamoto M., Matsushita M., Fujita T., and Nishioka K. Glycyrrhizin inhibits the lytic pathway of complement - possible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis. Microbiol. Immunol. 44 (2000) 799-804
17. Gao X., Tajima M., and Sairenji T. Nitric oxide down-regulates Epstein-Barr virus reactivation in epithelial cell lines. Virology 258 (1999) 375-381
18. Gershburg E., and Pagano J.S. Epstein-Barr virus infections: prospects for treatment. J. Antimicrob. Chemother. 56 (2005) 277-281
19. Gumpricht E., Dahl R., Devereaux M.W., and Sokol R.J. Licorice compounds glycyrrhizin and 18β-glycyrrhetinic acid are potent modulators of bile acid-induced cytotoxicity in rat hepatocytes. J. Biol. Chem. 280 (2005) 10556-10563
20. Hibasami H., Iwase H., Yoshioka K., and Takahashi H. Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells. Int. J. Mol. Med. 17 (2006) 215-219
21. Hoever G., Baltina L., Michaelis M., Kondratenko R., Baltina L., Tolstikov G.A., Doerr H.W., and Cinatl Jr. J. Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus. J. Med. Chem. 48 (2005) 1256-1259
22. Jeong H.G., and Kim J.Y. Induction of inducible nitric oxide synthase expression by 18β-glycyrrhetinic acid in macrophages. FEBS Lett. 513 (2002) 208-212
23. Kawakami F., Shimoyama Y., and Ohtsuki K. Characterization of complement C3 as a glycyrrhizin (GL)-binding protein and the phosphorylation of C3α by CK-2, which is potently inhibited by GL and glycyrrhetinic acid in vitro. J. Biochem. 133 (2003) 231-237
24. Kondratenko R.M., Baltina Jr. L.A., Baltina L.A., Baschenko N.Z., and Tolstikov G.A. Synthesis and immunomodulating activity of new glycopeptides of glycyrrhizic acid containing residues of l-glutamic acid. Bioorg. Khim. 32 (2006) 660-666
25. Lambris J.D., Ganu Y.S., Hirami S., and Müller-Eberhard H.J. Mapping of the C3d receptor (CR2) binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 4235-4239
26. Lin J.-C. Strategies for evaluation of antiviral agents against Epstein-Barr virus in culture. In: Kinchington D., and Schinazi R.F. (Eds). Methods in Molecular Medicine: Antiviral Chemotherapy Protocols (2000), The Humana Press Inc., New Jersey 139-150
27. Lin J.-C. Mechanism of action of glycyrrhizic acid in inhibition of Epstein-Barr virus replication in vitro. Antiviral Res. 59 (2003) 41-47
28. Lin J.-C. Pathogenesis and therapy of Epstein-Barr virus infection: novel therapeutic approaches. In: Umar C.S. (Ed). New Developments in Epstein-Barr Virus (2006), Nova Science Publishers, Inc., New York 1-35
29. Lin J.-C., and Machida H. Comparison of two bromovinyl nucleoside analogs, 1-β-d-arabinofuranosyl-E-5-(2-bromovinyl)uracil and E-5-(2-bromovinyl)-2′-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication. Antimicrob. Agents Chemother. 32 (1988) 1068-1072
30. Lin J.-C., and Pagano J.S. Sequential detection of different antigens induced by Epstein-Barr virus and herpes simplex virus in the same Western blot by using dual antibody probes. J. Virol. 59 (1986) 522-524
31. Lin J.-C., Smith M.C., Cheng Y.C., and Pagano J.S. Epstein-Barr virus: inhibition of replication by three new drugs. Science 221 (1983) 578-579
32. Lin J.-C., Smith M.C., and Pagano J.S. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J. Virol. 50 (1984) 50-55
33. Lin J.-C., Smith M.C., and Pagano J.S. Comparative efficacy and selectivity of some nucleoside analogs against Epstein-Barr virus. Antimicrob. Agents Chemother. 27 (1985) 971-973
34. Lin J.-C., Nelson D.J., Lambe C.U., and Choi E.I. Metabolic activation of 9([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human lymphoblastoid cell lines infected with Epstein-Barr virus. J. Virol. 60 (1986) 569-573
35. Lin J.-C., De Clercq E., and Pagano J.S. Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrob. Agent Chemother. 31 (1987) 1431-1433
36. Lin J.-C., De Clercq E., and Pagano J.S. Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, on Epstein-Barr virus replication. Antimicrob. Agents Chemother. 35 (1991) 2440-2443
37. Lin J.-C., Reefschläger J., Herrmann G., and Pagano J.S. Structure-activity relationship between (E)-5-(2-bromovinyl)-and 5-vinyl-1-β-d-arabinofuranosyluracil(BV-araU, V-araU) in inhibition of Epstein-Barr virus replication. Antiviral Res. 17 (1992) 43-52
38. Lo Y.M.D., Chan L.Y.S., Lo K.W., Leung S.F., Zhang J., Chan A.T.C., Lee J.C.K., Hjelm N.M., Johnson P.J., and Huang D.P. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 59 (1999) 1188-1191
39. Mannick J.B., Asano K., Izumi K., Kieff E., and Stamler J.S. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 79 (1994) 1137-1146
40. Mar E.C., Chu C.K., and Lin J.-C. Some nucleoside analogs with anti-human immunodeficiency virus activity inhibit replication of Epstein-Barr virus. Antiviral Res. 28 (1995) 1-11
41. Nemerow G., Mold C.V., Keivens Schwend V., Tollefson V., and Cooper N.R. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp 350 and C3 complement fragment C3d. J. Virol. 61 (1987) 1416-1420
42. Nemerow G., Houghton R., Moore M., and Cooper N.R. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocytes Epstein-Barr virus receptor (CR2). Cell 56 (1989) 369-377
43. Nemerow G., Mullen J.J., Dickson P.W., and Cooper N.R. Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection. J. Virol. 64 (1990) 1348-1352
44. Shibata S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi 120 (2000) 849-862
45. Takeda S., Ishthara K., Wakui Y., Amagaya S., Maruno M., Akao T., and Kobashi K. Bioavailability study of glycyrrhetic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis. J. Pharm. Pharmacol. 48 (1996) 902-905
46. Tanner J., Weis J., Fearon D., Whang Y., and Kieff E. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 50 (1987) 203-213
47. van Rossum T.G., Vulto A.G., Hop W.C., Brouwer J.T., Niesters H.G., and Schalm S.W. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J. Gastroenterol. Hepatol. 14 (1999) 1093-1099
48. Zheng Q.-Z., and Lou Y.-J. Pathologic characteristics of immunologic injury in primary cultured rat hepatocytes and protective effect of glycyrrhizin in vitro. Acta Pharmacol. Sin. 24 (2003) 771-777